Results 211 to 220 of about 11,165,306 (334)

NKCC1: A key regulator of glioblastoma progression

Molecular Oncology, EarlyView.
Glioblastoma (GBM) progression is driven by disrupted chloride cotransporter homeostasis. NKCC1 is highly expressed in stem‐like, astrocytic, and progenitor cells, correlating with earlier recurrence, while overall survival remains unaffected. NKCC1 serves as a prognostic marker and potential therapeutic target, linking chloride transporter imbalance ...
Anja Thomsen, Diana Freitag, Madlen Haase, Christian Senft, Falko Schwarz, Silke Keiner   +5 more
wiley   +1 more source

Transcriptional profiling of circulating extracellular vesicles from prebiopsy prostate cancer patients

Molecular Oncology, EarlyView.
RNA profiling of circulating extracellular vesicles (EVs) from blood samples of men undergoing prostate biopsy identifies transcripts associated with clinically significant prostate cancer. Integrative analysis with public tumor datasets links EV‐derived gene signatures to tumor stage and progression‐free survival, highlighting CASP3, XRCC2, and RIT1 ...
Stefan Werner, Pierre Tennstedt, Randi C. Pose, Christian Müller, Katharina Besler, Svenja Schneegans, Malik Alawi, Marie C. Roesch, Sven Peine, Desiree Bonci, Joanna Budna‐Tukan, Evi Lianidou, Catherine Alix‐Panabières, Derya Tilki, Klaus Pantel   +14 more
wiley   +1 more source

Application of HEART, GRACE 2.0 and TIMI scores for risk stratification of chest pain: a single-centre external pilot study in a Sri Lankan population. [PDF]

Int J Emerg Med
Welhenge C, Fernando KM, Fernando JN, Deshapriya PC, Lekamge MLD, Kasturiratne A, De Silva AP.   +6 more
europepmc   +1 more source

Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2‐COL3A1 axis

Molecular Oncology, EarlyView.
CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak, Iva Staniczková Zambo, Matěj Přikryl, Peter Múdry, Danica Zapletalová, Jarmila Navrátilová, Jiří Navrátil, Jan Šmarda, Liudmyla Drobot, Petr Beneš, Lucia Knopfová   +10 more
wiley   +1 more source

CTA imaging characteristics and endovascular therapy effect in patients with large ischemic stroke: a prospective cohort study. [PDF]

Neurol Res Pract
Deng W, Zhu X, Han J, Sun Y, Nan G.
europepmc   +1 more source

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

Molecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen, Kristiane Søreng, Chiara Veroni, Laura Trachsel‐Moncho, Nagham Asp, Robin Gaupset, Lars Gustav Lyckander, Helene Knævelsrud, Lars Eftang, Anne Simonsen   +9 more
wiley   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Implementing the Lung Donor (LUNDON) acceptability score in U.S. donor management and transplant decision-making: A multi-aim, mixed-methods protocol. [PDF]

PLoS One
Rossetti NE, Morrison S, Chang SH, Yan Y, Jaensch-Frie G, Liu CR, Seyoum NY, Katta M, Kumar A, Yang Z, Oncken C, Hamilton C, Schroy N, Stumbaugh K, Marklin G, Heiden B, Cummiskey B, Peskoe S, Hartwig M, Puri V, Baumann AA.   +20 more
europepmc   +1 more source

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source

Quality of life in Turkish children with interstitial lung disease: Insights from the National chILD Registry. [PDF]

Eur J Pediatr
Kekec H, Sismanlar Eyuboglu T, Aslan AT, Ulgen O, Ozcaglar A, Polat ZB, Bankoglu Parlak B, Bingol A, Karabulut S, Eralp EE, Korkmaz C, Oztosun B, Kartal Ozturk G, Girgin Dindar B, Akgul Erdal M, Kavgacı U, Olgun EG, Ayman FN, Uyan ZS, Ozsezen B, Ramaslı Gursoy T, Asfuroglu P, Serbes M, Hızal M, Nayır Buyuksahın H, Cavıldak Karaaslan G, Yalcın E, Emiralioglu N, Gökdemir Y, Pekcan S, Kılınc Sakallı AA, Girit S, Cobanoglu N, Cinel G, Oguz B, Orhan D, Ceylan AC, Kiper N.   +37 more
europepmc   +1 more source